Swiss team develops imaging technique to aid drug delivery in constricted blood vessels

In the interest of designing new nano-sized vehicles for cardiovascular drugs, Swiss researchers have developed an X-ray technique for visualizing blood vessels that have been constricted by atherosclerosis.

Smallest, fastest nanomotor moves drugs and releases them on demand

Mobility is an important function of any drug-delivering robot--even a well-designed machine that ultimately can't get where it's needed serves little to no purpose. To this end, researchers have developed a wide range of innovative devices from microrockets to DNA propellers to sperm-driven robots.

Phosphagenics' animal health topical patch shows promise

Phosphagenics' TPM/Oxycodone topical patch to combat neuropathic pain in large companion animals relieved all racehorses within two days in an initial study, the company said May 21.

Stem cells loaded with herpesvirus attack glioblastoma brain tumors in mice

Glioblastoma multiforme, the most common and one of the most aggressive forms of brain cancer, is notoriously difficult to treat. Now, researchers have developed a novel method of dealing with the disease: They're infecting the tumor with herpesvirus, shuttled into the brain in stem cells.

New data boost Insmed's inhaled liposomal delivery mechanism for lung infections

Insmed's Phase II trial of Arikayce, or inhaled liposomal amikacin for the treatment of nontuberculous mycobacterial lung infections, did not meet its primary endpoint, but new data released May 20 from the 84-day open-label extension show that patients receiving the compound showed significant improvement, the company said.

Reckitt Benckiser to develop nasal spray for emergency overdose of opioids

Reckitt Benckiser Pharmaceuticals announced May 19 that it is codeveloping what would be the first nasally administered naloxone-based therapy to treat emergency cases of opioid overdose from heroin or prescription painkillers.

UC Davis team isolates fungus enzyme to cross blood-brain barrier

At the American Society for Microbiology's annual meeting this week, a team of researchers from the University of California, Davis, demonstrated a study showing that silicon nanoparticles they designed could penetrate the blood-brain barrier.

UPDATED: Alnylam's hepatitis B therapy shows promise in animal studies

RNAi specialist Alnylam is adding a hepatitis B virus therapy to its pipeline of candidates that employ its Enhanced Stabilization Chemistry-GalNAc-conjugate technology enabling subcutaneous dosing and plans to file an IND by the end of 2015.

Nanoparticles weaken and then kill cancer cells with two-drug timed release

Scientists at MIT have engineered a one-two punch for cancer that carries two drugs at a time and has been shown to shrink lung and breast tumors in mice. While other nanoparticles have carried multiple drugs, this one makes use of a specific timing mechanism to get the most out of each treatment.

North Carolina State researchers 'smuggle' drugs into cancer cells with ATP

North Carolina State researchers have developed a method to "smuggle" cancer drugs into cancer cells, enabling delivery of the treatment within the cell itself.

Boston College team makes zinc nano-cages for 'smart' cancer drug delivery

Researchers at Boston College have created a small cage out of metals and organic materials that can act as a "smart" delivery vehicle to carry cancer drugs.

MIT researchers deliver low doses of siRNA to lung endothelial cells

One of the chief drawbacks of RNA interference therapies so far has been the difficulty of delivering small interfering RNA to cells outside the liver. That's why a newly reported breakthrough in delivering siRNA to endothelial cells in the lung and other organs is a big deal.

Tonix's sublingual formulation for fibromyalgia reaches pivotal trial stage

Tonix Pharmaceuticals has completed enrollment in the 200-patient, placebo-controlled BESTFIT trial of sublingually delivered cyclobenzaprine for the treatment of fibromyalgia. 

Boston Scientific launches Promus Premier drug-eluting stent in Japan

Boston Scientific rolled out its Promus Premier next-generation drug-eluting coronary stent system in Japan, part of the company's sales and marketing strategy as it looks for a blockbuster product to kick-start its revenue growth.

Icon begins pivotal late-stage trial of sustained-release postsurgery cataract treatment

Icon Biosciences has advanced its sustained-release therapy for inflammation after cataract surgery to a pivotal late-stage study. With one injection postsurgery, Icon's platform releases anti-inflammatory drugs that currently require multiple topical applications daily.

Direct injection of drugs to back of eye shows potential

Clearside Biomedical presented human and animal study data showing the benefits of directly injecting medication into the eye's posterior suprachoroidal space at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.

Double-locked virus needs two enzyme 'keys' to release drugs

Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.

Braeburn Pharmaceuticals to clinically test subdermal implant for treatment of opioid dependence

Braeburn Pharmaceuticals received the go-ahead from the FDA to initiate a new clinical trial of implants for the continuous subdermal delivery of buprenorphine to combat opioid dependence.

Novel glaucoma drug delivery platform described at ARVO conference

Startup Envisia Therapeutics is presenting the results of its ophthalmology research and technology allowing intracameral drug delivery at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL. 

Civitas announces positive results from Phase II inhaled levodopa trial

Civitas Therapeutics announced that its inhaled formulation of levodopa for the treatment of "off episodes" associated with Parkinson's disease met its primary clinical endpoint in a Phase II trial.